David D Davidar, a director at $GMED, sold 25,000 shares of the company on 11-12-2025 for an estimated $2,150,005. We received data on the trade from a recent SEC filing. This was a sale of approximately 4.6% of their shares of this class of stock. Following this trade, they now own 516,275 shares of this class of $GMED stock.
$GMED Insider Trading Activity
$GMED insiders have traded $GMED stock on the open market 5 times in the past 6 months. Of those trades, 0 have been purchases and 5 have been sales.
Here’s a breakdown of recent trading of $GMED stock by insiders over the last 6 months:
- DAVID D DAVIDAR sold 25,000 shares for an estimated $2,150,005
- STEPHEN T ZARRILLI sold 25,000 shares for an estimated $2,107,257
- ANN D RHOADS has made 0 purchases and 3 sales selling 20,000 shares for an estimated $1,402,600.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$GMED Hedge Fund Activity
We have seen 246 institutional investors add shares of $GMED stock to their portfolio, and 297 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MADISON AVENUE PARTNERS, LP added 1,712,148 shares (+inf%) to their portfolio in Q2 2025, for an estimated $101,050,974
- JANUS HENDERSON GROUP PLC added 1,200,676 shares (+17.1%) to their portfolio in Q2 2025, for an estimated $70,863,897
- BOSTON TRUST WALDEN CORP added 1,185,461 shares (+inf%) to their portfolio in Q3 2025, for an estimated $67,891,351
- RTW INVESTMENTS, LP removed 1,125,000 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $66,397,500
- ANTIPODES PARTNERS LTD added 889,229 shares (+49020.3%) to their portfolio in Q3 2025, for an estimated $50,926,144
- DRIEHAUS CAPITAL MANAGEMENT LLC removed 873,784 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $51,570,731
- DIMENSIONAL FUND ADVISORS LP added 842,547 shares (+72.1%) to their portfolio in Q3 2025, for an estimated $48,252,666
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$GMED Congressional Stock Trading
Members of Congress have traded $GMED stock 3 times in the past 6 months. Of those trades, 1 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $GMED stock by members of Congress over the last 6 months:
- REPRESENTATIVE LISA C. MCCLAIN has traded it 3 times. They made 1 purchase worth up to $15,000 on 06/17 and 2 sales worth up to $30,000 on 07/10, 06/24.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
$GMED Analyst Ratings
Wall Street analysts have issued reports on $GMED in the last several months. We have seen 6 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Barclays issued a "Overweight" rating on 11/10/2025
- B of A Securities issued a "Buy" rating on 11/07/2025
- Truist Securities issued a "Buy" rating on 11/07/2025
- RBC Capital issued a "Outperform" rating on 11/07/2025
- Wells Fargo issued a "Overweight" rating on 11/07/2025
- Morgan Stanley issued a "Overweight" rating on 07/15/2025
To track analyst ratings and price targets for $GMED, check out Quiver Quantitative's $GMED forecast page.
$GMED Price Targets
Multiple analysts have issued price targets for $GMED recently. We have seen 8 analysts offer price targets for $GMED in the last 6 months, with a median target of $90.5.
Here are some recent targets:
- Matt Miksic from Barclays set a target price of $114.0 on 11/10/2025
- Shagun Singh from RBC Capital set a target price of $92.0 on 11/07/2025
- Craig Bijou from B of A Securities set a target price of $91.0 on 11/07/2025
- Richard Newitter from Truist Securities set a target price of $93.0 on 11/07/2025
- Vik Chopra from Wells Fargo set a target price of $79.0 on 11/07/2025
- Thomas Stephan from Stifel set a target price of $64.0 on 10/28/2025
- William Plovanic from Canaccord Genuity set a target price of $90.0 on 07/22/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
